Table 1.

Demographics and clinicopathologic characteristics of ALK-positive NSCLC patients.

	Pure EML4-ALK fusionsn (%)	Pure uncommonALK fusionsn (%)	ComplexALK fusionsn (%)	All patientsn (%)
Number of patients	53	19	26	98
Median age, years (range)	46 (25–76)	50 (30–69)	49 (28–70)	47.5 (25–76)
Gender
Male	22 (41.5)	10 (52.6)	15 (57.7)	47 (48.0)
Female	31 (58.5)	9 (47.4)	11 (42.3)	51 (52.0)
Smoking history
Yes	10 (18.9)	4 (21.1)	4 (15.4)	18 (18.4)
No	43 (81.1)	15 (78.9)	22 (84.6)	80 (81.6)
Histology
ADC	51 (96.2)	18 (94.7)	25 (96.2)	94 (96.0)
SCC	0 (0)	0 (0)	1 (3.8)	1 (1.0)
LCNEC	1 (1.9)	0 (0)	0 (0)	1 (1.0)
ASC	1 (1.9)	1 (5.3)	0 (0)	2 (2.0)
Disease stage
III	3 (5.7)	1 (5.3)	1 (3.8)	5 (5.1)
IV	50 (94.3)	18 (94.7)	25 (96.2)	93 (94.9)
PS score
0	2 (3.8)	0 (0)	0 (0)	2 (2.0)
1	46 (86.8)	17 (89.5)	23 (88.5)	86 (87.8)
2	5 (9.4)	2 (10.5)	3 (11.5)	10 (10.2)
Crizotinib (line of treatment)
1	34 (64.2)	11 (57.9)	17 (65.4)	62 (63.3)
2	14 (26.4)	7 (36.8)	7 (26.9)	28 (28.6)
3	5 (9.4)	0 (0)	2 (7.7)	7 (7.1)
5	0 (0)	1 (5.3)	0 (0)	1 (1.0)
Best clinical response for criztinib
CR	0 (0)	1 (5.3)	0 (0)	1 (1.0)
PR	35 (66.0)	12 (63.2)	20 (76.9)	67 (68.4)
SD	13 (24.5)	4 (21.1)	3 (11.5)	20 (20.4)
PD	5 (9.4)	2 (10.5)	3 (11.5)	10 (10.2)
Post-crizotinib ALK inhibitor treatment
Yes	36 (67.9)	12 (63.2)	15 (57.7)	63 (64.3)
No	11 (20.8)	2 (10.5)	3 (11.5)	16 (16.3)
NA	6 (11.3)	5 (26.3)	8 (30.8)	19 (19.4)
Palliative treatment for advanced NSCLC*
Yes	21 (39.6)	12 (63.2)	8 (30.8)	41 (41.8)
No	31 (58.5)	7 (36.8)	16 (61.5)	54 (55.1)
NA	1 (1.9)	0 (0)	2 (7.7)	3 (3.1)
Baseline brain metastasis
Yes	10 (18.9)	5 (26.3)	8 (30.8)	23 (23.5)
No	43 (81.1)	14 (73.7)	18 (69.2)	75 (76.5)

*Palliative treatments include local surgical therapy, palliative radiotherapy, and interventional therapy.